Your browser doesn't support javascript.
loading
Risk factors for local recurrence of upper extremity desmoid tumors.
Denwood, Hayley; Gonzalez, Marcos R; Sodhi, Alisha; Werenski, Joseph; Clunk, Marilee; Newman, Erik T; Lozano-Calderón, Santiago A.
Afiliação
  • Denwood H; Department of Orthopaedic Surgery, Harvard Medical School, Division of Orthopaedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Gonzalez MR; Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Sodhi A; Department of Orthopaedic Surgery, Harvard Medical School, Division of Orthopaedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Werenski J; Department of Orthopaedic Surgery, Harvard Medical School, Division of Orthopaedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Clunk M; Department of Orthopaedic Surgery, Harvard Medical School, Division of Orthopaedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Newman ET; Department of Orthopaedic Surgery, Harvard Medical School, Division of Orthopaedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lozano-Calderón SA; University of Toledo College of Medicine and Life Sciences Toledo, Toledo, Ohio, USA.
J Surg Oncol ; 129(4): 813-819, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38073165
ABSTRACT

INTRODUCTION:

Upper extremity (UE) desmoid tumors are locally aggressive neoplasms with high recurrence rates. Our study sought to analyze the demographics and treatment strategies of UE desmoid tumors and identify risk factors for recurrence. MATERIALS AND

METHODS:

A retrospective review of 52 patients with histologically confirmed UE desmoid tumors treated at our institution between 1990 and 2015 was conducted. Survival was assessed using the Kaplan-Meier method and the Cox proportional hazards model was used for risk factor analysis.

RESULTS:

For the entire cohort, median age was 40 (29-47) years, 75% were female, and 48% had local recurrence. The median tumor size was 45 (15-111) cm3 on imaging. Twenty-two patients had a previous resection. The most common treatments were surgery alone (50%) and surgery with adjuvant radiotherapy (21%). Tumor size ≥5 cm and tumor volume ≥40 cm3 on imaging were associated with increased recurrence (p = 0.006 and p = 0.005, respectively). Age and sex were not associated with local recurrence. Patients with a tumor size ≥5 cm were 2.6 times more likely to present with recurrence. At the 10-year mark, a lower local recurrence-free survival was seen in patients with tumors ≥5 cm (72.2% vs. 36.3%, p = 0.042) or ≥40 cm3 (67.2% vs. 32.7%, p = 0.034).

CONCLUSION:

In our study, only tumor dimensions appeared to modify recurrence risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibromatose Agressiva Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibromatose Agressiva Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article